Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Scientific Letter

[Translated article] Oxygen therapy. Considerations regarding its use in acute ill patients

Oxigenoterapia. Consideraciones sobre su uso en el enfermo agudo

To the Director:

The current SARS-CoV-2 pandemic offers an opportunity to reflect on the use of oxygen therapy in the management of acute respiratory failure that often accompanies Covid-19. At a time when scientific evidence filters all clinical practice, it is easy to see that oxygen therapy is often implemented in patients with acute respiratory failure with no real scientific basis.

Retrospective studies already show that excessive oxygen use does not improve the prognosis of critically ill patients, and that hyperoxia is associated with higher mortality. In the 1970s, Douglas et al. found that high oxygen levels (FiO2 > 0.7) increased pulmonary venous admixture due to the appearance of absorption atelectasis and the suppression of the hypoxic pulmonary vasoconstriction reflex. Other authors have shown that lower FiO2 levels (even only 0.3) can cause the same alterations in patients with pre-existing lung disease.

Excessive oxygen intake can impair gas exchange by increasing oxidative stress and inflammation (the Lorrain-Smith effect). In the current epidemiological context, oxidative stress has been placed in the spotlight by the recent description of the hypercytokinemia associated with SARS-CoV-2 pneumonia. Excessive doses of oxygen increase the production of reactive nitrogen and oxygen species (RNS, ROS), the recruitment and activation of inflammatory cells, and the release of pro-inflammatory mediators (IL-1α, IL-6, IL-8, or TNF-α), with local (lung damage and infection and sepsis) and distant (tissue damage and multiorgan failure) consequences. Although these effects are magnified when high FiO2 levels are maintained for prolonged periods (>12–24 h), shorter periods of hyperoxia are also associated with increased morbidity and mortality. Hyperoxia, then, could be an indirect marker of poor prognosis in severe patients.

Paradoxically, hyperoxia can reduce systemic oxygen consumption, probably due to the redistribution of blood flow to protect vital organs from the non-physiological effects of high FiO2 (functional shunt). Higher than normal levels of PaO2 also trigger arterioles vasoconstriction by local mechanisms, a phenomenon that could explain the worse progress of some patients with myocardial infarction, stroke, head injury, cardiac arrest, or sepsis. Tissue hyperoxia, furthermore, promotes lesion development in ischemia-reperfusion situations.

In short, hyperoxia can be as dangerous as hypoxemia. A multicenter retrospective study of 36,307 patients hospitalized in intensive care units (ICU) showed that PaO2 during the first 24 hours of admission was an independent predictor of hospital mortality. PaO2-related mortality formed an asymmetric U with a clear plateau at the end of the lowest PaO2 values, linear increase on the hyperoxia side, and lowest mortality rates at a PaO2 value between 110 and 150 mmHg (Fig. 1).

When expressed as a standardized mortality ratio, hyperoxia was a predictor of mortality at PaO2 values >125 mmHg.

A recent clinical trial in patients with septic shock had to be discontinued prematurely after evidence emerged of excess inhospital mortality in hyperoxic patients. Hyperoxia also appears to be of little benefit during recovery after cardiac arrest. Helmerhorst et al. showed in an observational study that in-hospital mortality after cardiorespiratory arrest was the same as in patients with normal oxygen levels (PaO2 55–80 mmHg).

Hyperoxia does not benefit patients with severe acute respiratory failure. The effect of exposure to excess FiO2 (FiO2 > 0.5 when PaO2 was >80 mmHg) was analyzed in a study in 2994 patients with acute respiratory distress syndrome (ARDS). This study found that the higher the cumulative exposure at 5 days, the higher the mortality, the number of days with mechanical ventilation, and the length of hospital stay. Mortality also affected patients with mild, moderate, or severe ARDS, which meant that the relationship observed between mortality and cumulative exposure to high FiO2 was independent of disease severity. A recent multicenter randomized trial in patients with ARDS confirmed that controlled...
oxygen therapy (PaO₂ 55–70 mmHg or SpO₂ 88%–92%) did not increase mortality at 28 days. 

Evidence in patients with acute chronic respiratory failure also supports controlling SpO₂ values. Plant et al. showed that excessive use of oxygen therapy in patients with chronic obstructive pulmonary disease exacerbations was associated with respiratory acidosis and a greater number of ICU admissions. The authors pointed out that therapy should focus on maintaining PaO₂ and SaO₂ at 55–75 mmHg and SaO₂ 85–92%, respectively. A subsequent controlled trial showed higher mortality among patients receiving oxygen therapy not adjusted to achieve SaO₂ values of 88%–92%

Acute respiratory care should, therefore, focus on improving lung function with the proper use of oxygen therapy, an approach that differs considerably from standard practice. Unnecessarily high FiO₂ levels reduce the window of opportunity for switching treatment or adjusting FiO₂ levels in the case of worsening respiratory status. In acutely hypoxic patients, an SpO₂ of 90%–94 seems to be a reasonable range. It accommodates normal fluctuations and is safe enough to prevent damage. High-flow systems (e.g., Venturi masks) that can be adjusted to achieve stable FiO₂ are recommended for oxygen administration. The idea of setting a minimum PaO₂ value to avoid tissue hypoxia should be discarded, and emphasis should be placed on setting a maximum safety value to avoid systemic toxicity (PaO₂ <120 mmHg). In patients with hypercapnic respiratory failure, the SpO₂ ranges should be lower (88%–92%) and ventilatory support (preferably non-invasive mechanical ventilation) should be considered if greater oxygen transport is needed (e.g., associated failure of other organs) or if hypercapnia persists despite controlled FiO₂ (0.24–0.4). High-flow nasal cannula may be an alternative or a supplement to non-invasive mechanical ventilation in more severe patients. In the specific case of patients with chronic obstructive pulmonary disease exacerbations, some guidelines recommend a maximum FiO₂ of 0.28, a practice that is also advisable in the prehospital setting. In the absence of hypoxemia, oxygen therapy should be avoided in patients with acute myocardial infarction, stroke, head injury, after cardiorespiratory arrest, and in patients with sepsis. In patients admitted to the ICU, restrictive oxygen therapy protocols (aimed at maintaining PaO₂ within the physiological range) are well tolerable and may improve prognosis.

In conclusion, a more liberal oxygen prescription is at odds with modern requirements for the development and approval of a treatment of any type. The use of automated oxygen flow titration devices could improve morbidity and mortality and reduce care costs, although they are unlikely to replace clinical monitoring. In the meantime, we must stress that oxygen is a drug that must be prescribed for defined indications where the benefits outweigh the risks, and that the dose, the delivery system, the duration of administration, and response monitoring must be clearly specified.

**Funding**

The authors declare that they have not received funding for this study.

**Conflict of interests**

The authors state that they have no conflict of interests.

**References**

1. Thomson AJ, David J, Webb DJ, Maxwell SRJ, Grant IS. Oxygen therapy in acute medical care. The potential dangers of hyperoxia need to be recognized. BMJ. 2002;324:1406–7.
2. De Jonge E, Peelen L, Keijzers PJ, Joore H, de Lange D, van der Voort PH, et al. The use of non-invasive ventilation in patients with exacerbations of chronic obstructive pulmonary disease in a general hospital setting: a randomised controlled trial. Crit Care. 2008;12:R156, http://dx.doi.org/10.1186/cc7150.
3. Helmerhorst RJ, Roos-Blom MJ, van Westerloo DJ, Abu-Hanna A, de Keijzer NF, de Jonge E. Associations of arterial carbon dioxide and arterial oxygen concentrations with hospital mortality after resuscitation from cardiac arrest. Crit Care. 2015;19:348, http://dx.doi.org/10.1186/s13054-015-1067-6.
4. Douglas M, Downs JR, Darbyshire DJ, Hedges JR, Martin MA. Changes in pulmonary venous admixture with varying inspired oxygen. Anesth Analg. 1976;55:688–95.
5. Downs JR. Has oxygen administration delayed appropriate respiratory care? Fallacies regarding oxygen therapy. Respir Care. 2003;48:611–20.
6. Chen LVC, Holland RL, Stukas S, Wellington CL, Sekhon MS. Confounding the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. Eur Respir J. 2020;56:2003006, http://dx.doi.org/10.1183/13993003.03006-2020.
7. Hafner S, Beloncle F, Koch A, Rademacher P, Asfar P. Hyperoxia in intensive care, emergency, and peri-operative medicine: Dr. Jekyll or Mr. Hyde? A 2015 update. Ann Intensive Care. 2015;5:42, http://dx.doi.org/10.1186/s13613-015-0084-6.
8. Damiani E, Donati A, Girardis M. Oxygen in the critically ill: friend or foe? Curr Opin Anesthesiol. 2018;31:129–35.
9. Asfar P, Schortgen F, Boisramé-Helms J, Charpentier J, Guevrot E, Megarbane B, et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERSS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respir Med. 2017;5:180–90, http://dx.doi.org/10.1016/S2213-2600(17)30046-2.
10. Aggarwal NR, Brower RG, Hager DN, Thompson BT, Netzer G, Shankoltz C, et al. Oxygen exposure resulting in arterial oxygen tensions above the protocol goal was associated with worse clinical outcomes in acute respiratory distress syndrome. Crit Care Med. 2018;46:517–24, http://dx.doi.org/10.1097/CCM.0000000000002886.
11. Barrot L, Asfar P, Mauny F, Winnisiewski H, Montinti F, Radie J, et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. N Engl J Med. 2020;382:999–1008, http://dx.doi.org/10.1056/NEJMoa1916431.
12. Plant PK, Owen JL, Elliott MW. One year prevalence study of respiratory acidosis in acute exacerbations of COPD: implications of non-invasive ventilation and oxygen administration. Thorax. 2000;55:550–4, http://dx.doi.org/10.1136/thorax.55.7.550.
13. Austin MA, Wills KE, Blizard I, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in acute exacerbations of obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ. 2010;341:c5462, http://dx.doi.org/10.1136/bmj.c5462.
14. Segovia B, Velasco D, Jauregucio Org A, Díaz Lobato S. Combination therapy in patients with acute respiratory failure: high-flow nasal cannula and non-invasive mechanical ventilation. Arch Bronconeumol. 2019;55:166–7.
15. O’Driscoll BR, Howard LS, Davison AG. BTS guideline for emergency oxygen use in adult patients. Thorax. 2008;63 Suppl V:v1–68, http://dx.doi.org/10.1136/thx.2008.102947.
16. Mayoralas-Altés S, Carratalá JM, Díaz-Lobato S. New perspectives in oxygen therapy titration: is automatic titration the future? Arch Bronconeumol. 2019;55:319–27.
17. Dodd ME, Kellett F, Davis A, Simpson JCG, Webb AK, Haworth CS, et al. Audit of oxygen prescribing before and after the introduction of a prescription chart. BMJ. 2000;320:864–5.

José Manuel Valencia Gallardo a,*, Jordi Solé Viólan b, Felipe Rodríguez de Castro a

a Servicio de Neumología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain
b Servicio de Medicina Intensiva, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain

*Corresponding author.
E-mail address: jvalgal@gmail.com (J.M. Valencia Gallardo)